1. Home
  2. JYNT vs AKBA Comparison

JYNT vs AKBA Comparison

Compare JYNT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JYNT
  • AKBA
  • Stock Information
  • Founded
  • JYNT 2010
  • AKBA 2007
  • Country
  • JYNT United States
  • AKBA United States
  • Employees
  • JYNT N/A
  • AKBA N/A
  • Industry
  • JYNT Multi-Sector Companies
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • JYNT Miscellaneous
  • AKBA Health Care
  • Exchange
  • JYNT Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • JYNT 163.0M
  • AKBA 293.4M
  • IPO Year
  • JYNT 2014
  • AKBA 2014
  • Fundamental
  • Price
  • JYNT $10.87
  • AKBA $1.35
  • Analyst Decision
  • JYNT Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • JYNT 2
  • AKBA 2
  • Target Price
  • JYNT $18.00
  • AKBA $5.75
  • AVG Volume (30 Days)
  • JYNT 33.1K
  • AKBA 1.9M
  • Earning Date
  • JYNT 08-08-2024
  • AKBA 11-06-2024
  • Dividend Yield
  • JYNT N/A
  • AKBA N/A
  • EPS Growth
  • JYNT N/A
  • AKBA N/A
  • EPS
  • JYNT N/A
  • AKBA N/A
  • Revenue
  • JYNT $120,071,078.00
  • AKBA $174,497,000.00
  • Revenue This Year
  • JYNT $1.50
  • AKBA N/A
  • Revenue Next Year
  • JYNT N/A
  • AKBA $3.23
  • P/E Ratio
  • JYNT N/A
  • AKBA N/A
  • Revenue Growth
  • JYNT 7.46
  • AKBA N/A
  • 52 Week Low
  • JYNT $7.31
  • AKBA $0.78
  • 52 Week High
  • JYNT $17.82
  • AKBA $2.48
  • Technical
  • Relative Strength Index (RSI)
  • JYNT 34.42
  • AKBA 45.89
  • Support Level
  • JYNT $10.89
  • AKBA $1.27
  • Resistance Level
  • JYNT $11.46
  • AKBA $1.58
  • Average True Range (ATR)
  • JYNT 0.31
  • AKBA 0.09
  • MACD
  • JYNT 0.05
  • AKBA -0.02
  • Stochastic Oscillator
  • JYNT 12.16
  • AKBA 25.81

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: